Video

Dr. Lopategui on the Evolution of Molecular Testing in NSCLC

Jean Lopategui, MD, discusses the evolution of molecular testing in non–small cell lung cancer.

Jean Lopategui, MD, associate professor of pathology and director of Translational Genomics and of the Molecular Genetics Pathology Fellowship at Cedars-Sinai, discusses the evolution of molecular testing in non—small cell lung cancer (NSCLC).

Lung cancer, particularly NSCLC, has been the poster child for molecular testing, says Lopategui. The number of tests that are available to define and predict response to treatment is very high in this space. The field used to perform several tests in the past to categorize each of the genes and their mutations; this was time consuming and expensive, adds Lopategui. Today, next-generation sequencing is available, and this testing allows physicians to test multiple genes and mutations in just 1 test, concludes Lopategui.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD